Virax Biolabs Reports Significant Drop in Revenues to $6,331 for FY 2025, Marking Sharp Decline from $156,419 in Previous Year

Reuters
03 Jul
<a href="https://laohu8.com/S/VRAX">Virax Biolabs</a> Reports Significant Drop in Revenues to $6,331 for FY 2025, Marking Sharp Decline from $156,419 in Previous Year

Virax Biolabs Group Ltd. has released its financial results for the fiscal year ending March 31, 2025. The company reported revenues of $6.331 million, a significant decrease from $156.419 million in the previous year, 2024. The cost of revenues also saw a reduction, recorded at $59.398 million for 2025 compared to $105.829 million in 2024. Virax Biolabs experienced a gross loss of $53.067 million in 2025, contrasting with a gross profit of $50.590 million in 2024. Operating expenses included general and administrative costs of $4.330 million, slightly down from $4.595 million the previous year. Research and Development expenses were $1.780 million in 2025, compared to $1.562 million in 2024. Notably, there was no impairment of intangible assets in 2025, whereas 2024 saw an impairment of $390,355. Virax Biolabs, a global biotechnology firm focused on viral disease prevention, detection, and diagnosis, continues to emphasize its development in T cell in vitro diagnostics. The company does not provide specific guidance or outlook, citing the unpredictability of outcomes in its research and development efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-093260), on July 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10